白雲山(00874.HK)訂立增資協議
格隆匯5月28日丨白雲山(00874.HK)公告,於2025年5月28日,董事會批準公司訂立增資協議。根據該協議,公司、廣藥創投基金、廣州老字號基金分別向白雲山生物增資人民幣15,000.00萬元、人民幣13,000.00萬元和人民幣2,000.00萬元,白雲山生物的其他股東將放棄就本次增資行使其優先認購權。本次增資完成後,白雲山生物的註冊資本將由人民幣8,400.00萬元增加至人民幣12,053.5909萬元。公司於白雲山生物的直接及間接持股比例將維持不變,仍爲50.00%。
生物製藥產業是國家戰略性新興產業,是推動醫藥健康產業高質量發展的重要抓手。白雲山生物爲公司生物製藥領域的重要附屬公司,主要從事人用狂犬病疫苗(Vero細胞)的研發、生產和銷售,是公司實施創新驅動發展戰略和產業升級的重要載體,對於公司具有重要的戰略意義。目前,白雲山生物正在加緊推進人用狂犬病疫苗(Vero細胞)PM株產品生產批件申報等相關工作,急需股東資金支持。公司本次聯合廣藥創投基金、廣州老字號基金對白雲山生物增資,旨在解決白雲山生物的資金問題,支持白雲山生物儘快獲取新產品批文並投入生產,有助於公司生物製藥業務發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.